Trinity Biotech's Hb9210™ Analyzer Earns IFCC Gold Classification
Event summary
- Trinity Biotech's Premier Hb9210™ HbA1c Analyzer achieved the IFCC Gold Classification for 2026, the only system to do so.
- The next-generation Buffer A Plus column system enhances usability, reduces costs, and maintains high patient care standards.
- The global HbA1c testing market is valued at over $2 billion annually and projected to reach $3.5 billion by 2030.
- Trinity Biotech executives are attending the World Health Expo from February 10-12, 2026, to discuss advancements in diabetes care.
The big picture
Trinity Biotech's achievement underscores its growing influence in the diabetes care market, particularly as the global incidence of diabetes rises. The IFCC Gold Classification positions the company as a leader in precision diagnostics, setting a new benchmark for HbA1c measurement technology. With a cumulative investment of nearly $100 million in diabetes care technologies, Trinity Biotech is poised to capitalize on the expanding market for laboratory HbA1c testing, projected to surpass $3.5 billion by 2030.
What we're watching
- Market Penetration
- How Trinity Biotech will leverage the IFCC Gold Classification to expand its market share in the $2 billion HbA1c testing market.
- Technological Advancements
- The pace at which Trinity Biotech can integrate AI-powered continuous glucose monitoring (CGM+) into its product lineup.
- Regulatory Compliance
- Whether Trinity Biotech can sustain its leadership position amid increasing regulatory scrutiny and competition in the diabetes care sector.
Related topics